TrialThe Journal of urology2022

Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial.

K Kent Chevli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.